Skip to main content
. 2022 Jan 10;269(4):1764–1772. doi: 10.1007/s00415-021-10958-z

Fig. 4.

Fig. 4

Longitudinal dynamics of new treatment prescription, according to type of treatment prescription. a First-line treatments. b Anti-CD20 drugs. c Other second-line treatment. d Natalizumab treatment. *In figure c, other second-line treatment comprises natalizumab, fingolimod, cladribine and alemtuzumab. **Dash lines represent ± 2 standard deviations the mean number of new treatment prescriptions during the whole study period